Submit Deal

ARTEGRAFT

Summary

Artegraft processes and sells biologic vascular grafts that are derived from bovine carotid arteries and are implanted primarily in hemodialysis access patients.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 73 M

Avg. Deal Size£ 73 M

Market Context

Senior Management

Rick Gibson
CEO
Norris Horn
CFO

Sort

22 Jun 2020|United States|Medical Equipment

Target: ARTEGRAFT

Bidder: LAMAITRE VASCULAR

7 Service Providers

3 Target | 4 Bidder

24 Dealmakers

14 Target | 10 Bidder

£ 72 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy